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Abstract
Background: Lymphatic filariasis (LF) is one of the primary causes of lymphoedema in sub-Saharan Africa, and has
a significant impact on the quality of life (QoL) of those affected. In this paper we assess the relative impact of
lymphoedema on mobility and income in Chikwawa district, Malawi.
Methods: A random sample of 31 people with lymphoedema and 31 matched controls completed a QoL
questionnaire from which both an overall and a mobility-specific score were calculated. Two mobility tests were
undertaken, namely the 10 m walking test [10MWT] and timed up and go [TUG] test, and a subset of 10 cases-
control pairs wore GPS data loggers for 3 weeks to measure their mobility in a more natural setting. Retrospective
economic data was collected from all 31 case-control pairs, and each participant undertaking the GPS activity
recorded daily earnings and health expenditure throughout the observation period.
Results: Cases had a significantly poorer overall QoL (cases = 32.2, controls = 6.0, P < 0.01) and mobility-specific
(cases = 43.1, controls = 7.4, P < 0.01) scores in comparison to controls. Cases were also significantly slower (P < 0.01)
at completing the timed mobility tests, e.g. mean 10MWT speed of 0.83 m/s in comparison to 1.10 m/s for
controls. An inconsistent relationship was observed between mobility-specific QoL scores and the timed test
results for cases (10MWT correlation = −0.06, 95% CI = (−0.41, 0.30)), indicating that their perceived disability
differed from their measured disability, whereas the results were consistent for controls (10MWT correlation = −0.61,
95% CI = (−0.79, −0.34)). GPS summaries indicated that cases generally walk shorter distances at slower speeds than
control, covering a smaller geographical area (median area by kernel smoothing: cases = 1.25 km2, controls = 2.10 km2,
P = 0.16). Cases reported earning less than half that earned by controls per week (cases = $0.70, controls = $1.86,
P = 0.064), with a smaller proportion of their earnings (16% vs 22%, P = 0.461) being spent on healthcare.
Conclusions: Those affected by lymphoedema are at a clear disadvantage to their unaffected peers, experiencing a
lower QoL as confirmed by both subjective and objective mobility measures, and lower income. This study also
indicates that objective measures of mobility may be a useful supplement to self-assessed QoL questionnaires when
assessing the future impact of lymphoedema management interventions.
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Background
Lymphoedema, a chronic condition seen clinically as
localised swelling commonly in the legs or arms, is one
of the classical clinical symptoms of lymphatic filariasis
(LF), with approximately 17 million being affected glo-
bally [1]. In addition to the swelling, which can cause
discomfort and problems with mobility [2], those with
filarial lymphoedema are frequently affected by repeated
episodes of acute dermatolymphangioadenitis (ADLAs),
referred to as acute attacks. These attacks, which include
pain, fever and increased swelling of affected areas can
be extremely debilitating and are further associated with
the progression of the severity of the lymphoedema. To-
gether, lymphoedema and acute attacks have a signifi-
cant social [3], psychological [4, 5] and economic [6, 7]
impact on the affected individual. As such, the Global
Programme to Eliminate Lymphatic Filariasis (GPELF)
recognises that in order to eliminate LF as a public
health problem, these conditions need to be effectively
managed [8, 9]. Lymphoedema management primarily
consists of simple hygiene measures such as frequent
washing and exercise, with there being strong evidence
that these measures lower the number of acute attacks,
improve self-assessed quality of life, and decrease
swelling [10].
In Malawi, the national LF elimination programme has
been very successful in reducing the transmission of the
disease through annual mass drug administration with
ivermectin and albendazole [11, 12], and is now in a
position to focus on reducing the associated morbidity
burden. Recent studies in Chikwawa district, Southern
Region have focused on quantifying the number of
people affected by the clinical symptoms of LF [13, 14],
and measuring the self-assessed quality of life of those
affected [15]. These studies involved classifying the
severity of lymphoedema into three categories (mild,
moderate, severe), corresponding to Dreyer stages 1–2,
3–5 and 5–7 respectively, according to the degree of
swelling and the presence of skin folds [13, 16]. Whilst
Martindale et al. [15] provided a valuable insight into
the burden placed on those affected by their condition,
their study was limited to subjective measures of
quality of life/disability, and no comparison was made
between those affected and the remainder of the local
population.
The purpose of this present study therefore was to
assess the relative impact of filarial lymphoedema on
quality of life using a case-control paradigm. The study
primarily focuses on the physical impact of the
condition, and uses both subjective and objective mea-
sures to compare participants’ perceived and observed
mobility in both test and natural settings. A secondary
aim was to obtain information on income and health ex-
penditure in order to make comparison between the two
groups.
This study provides valuable information to national
LF programmes and their donors in an approach that
can be used in quantifying the impact of LF morbidity.
Further, it provides a framework that can be used to as-
sess the benefit of future morbidity interventions e.g.
lymphoedema management activities or clinical drug
trials [17].
Methods
Individuals affected by LF clinical conditions from two
health centre catchment areas (Nchalo and Bereu) in
Chikwawa district, Southern Region, Malawi were in-
cluded in this study, which was conducted in May 2015.
Clinical cases were identified and recruited based on
data from a previous morbidity mapping study in March
2014 [14], which identified 54 lymphoedema patients (36
in Nchalo, 18 in Bereu). A total of 31 lymphoedema pa-
tients included in this study to ensure that the study had
sufficient power (80%) to detect a mean quality of life
(QoL) score difference (described below) as little as 8
between cases and controls using a significance level of
5%. Stratified random sampling was used to select the 31
cases, using catchment area and severity of condition as
strata i.e. strata of Dreyer stages 1–4 (44/54 previously
identified patients) and 5–7 (10/54 previously identified
patients) as assessed during case identification. All forms
of identified lymphoedema (leg, arm, and breast) were
considered for this part of the study. One control per
case was then selected, matched by village, sex and ap-
proximate age. Population registers maintained by the
senior health surveillance assistant (HSA) of each catch-
ment area were used to select a minimum of four poten-
tial controls per case of which one was randomly
selected for inclusion in the study.
Quality of Life (QoL) questionnaire
Each case and matched control completed a self-
assessed QoL questionnaire to determine their physical
and psychological health, their ability to care for
themselves and undertake regular activities, and their
economic well-being (see Additional file 2). The ques-
tionnaire was adapted from the LF-specific Quality of
Life Questionnaire (LFSQQ) derived by Aggithaya et al.
(2013) to assess lymphoedema patients in India [18].
Modifications were made to this questionnaire in con-
sultation with local health workers in order to ensure
that the questions were culturally relevant. For example,
the original questionnaire included separate questions as
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to whether they experienced any difficulty in using an
Indian toilet or a European toilet. This was altered to a
single question to determine whether participants had
any difficulty using a local toilet. Participants were asked
to assess their ability to complete a list of tasks on a
scale of 0 (no problem completing the task) to 4
(extreme problem completing the task). There were five
tasks for each of the five QoL categories (mobility, self-
care, usual activities, psychological health, social partici-
pation), resulting in a total of 25 questions. The overall
QoL score was calculated as a percentage by summing
all the scores and dividing this total by 4 × Number of
questions answered. Comparisons of the overall QoL
scores, and scores obtained in each of the five categories
(sum of individual category scores/ [4 × Number of ques-
tions answered]), were made between cases and controls
to assess the perceived relative impact of lymphoedema.
Each case was also asked questions about their condition
including the number of acute attacks they had experi-
enced in the previous 6 months, how long the attacks
usually lasted, and whether they felt their lymphoedema
affected their ability to work.
Timed mobility tests
In addition to measuring perceived mobility problems
on the 0 to 4 scale (sitting or getting out of a chair, lying
down or standing up from the floor, going up steps,
walking for one hour without a break, using public
transport), objective measures of mobility were recorded.
Each participant completed a 10 m walking test (10MWT)
[19] and a timed ‘up and go’ (TUG) test [20, 21] which
measure gait speed and balanced walking ability respect-
ively. The 10MWT required participants to walk for 10 m
from a static start without assistance, and the time taken
to walk the intermediate 6 m was recorded. Assistive de-
vices were allowed if required, and participants were
instructed to walk at a comfortable and safe speed. The
timed test was repeated three times sequentially with a
short break (~1 min) between each test, and the average
time was recorded. The TUG test, which was undertaken
immediately after the 10MWT, required participants to
start from a seated position, and the time it took for the
participant to stand up, walk to a point three metres from
the chair, turn around, walk back to the chair then sit
down was recorded. As with the 10MWT, participants
were asked to walk at a comfortable speed, the test was re-
peated three times sequentially with a short break in be-
tween, and the average time was recorded. Average times
were compared between cases and controls to obtain a
more objective assessment of relative impact of lymphoe-
dema on mobility. The Pearson correlation coefficient be-
tween the self-assessed scores and the timed tests were
calculated to determine differences in perceived and actual
disability.
Natural mobility measures
A subset of 10 matched pairs, with a focus on leg lym-
phoedema only, also had their mobility measured in a
more natural environment over a period of 3 weeks
using GPS data loggers, specifically the i-gotU GT-120
(http://www.i-gotu.com/). Each participant was instructed
to wear the device on their arm during waking hours, and
the device recorded their GPS location every 60 s. Partici-
pants were visited by the research team every other day
throughout a 3 week period (excluding Sunday) during
which the GPS data logger was swapped for a fully
charged device, and the previous 2 days of data was
downloaded and stored. The data were cleaned by re-
moving any single points that were clearly inaccurate,
and further excluding points during which it appeared
that public transport (bicycle, minibus) was being
used i.e. if their speed exceeded 6.5 km/h. Further,
each point was categorised as either stationary or
walking based on a speed threshold of 0.5 km/h.
Minimum convex polygons and kernel density estimation
were used to identify each participant’s ‘activity area’ or
‘home range’ [22]. The minimum convex polygon is the
smallest possible convex polygon that encloses all (or a
subset of ) the recorded GPS points. This method is
commonly used to assess the home range of animals,
and assumes that the subject of interest moves
around the entire area indiscriminately. However, as
people tend to move along defined routes e.g. roads,
pathways, this method may not be a true representa-
tion of the area around which human subjects move.
Kernel density smoothing results in a smoothed sur-
face representing the density of recorded GPS points
over the area of interest [22, 23]. Using this method,
the 99% activity area is estimated as the smallest area
over which the kernel density sums to 0.99. The
minimum convex polygon home range and the kernel
density activity area were calculated using the R pack-
age adehabitatHR [24], and maps of the results were cre-
ated in QGIS version 2.12.0 [25], using OpenStreetMap
data (openstreetmap.org) as a base map.
Summaries of mobility were then calculated and com-
parisons made between cases and control using the non-
parametric Wilcoxon signed-rank test i.e. the average
daily moving distance, average daily walking distance,
average walking speed and size of activity area. To deter-
mine whether there was any consistency between the
self-assessed mobility scores, the timed mobility tests,
and the GPS results, the Kendall rank correlation coeffi-
cient, commonly known as Kendall’s tau, was calculated
for both cases and controls [26, 27]. Kendall’s tau is a
non-parametric test for correlation that is similar to
Spearman’s rank, but is less sensitive to outliers.
Kendall’s tau ranges between +1 (perfectly matched
ranking) and −1 (fully discordant ranking).
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Income and health expenditure
In addition to completing the self-assessed QoL ques-
tionnaire, all 31 cases and controls were also asked to
provide socioeconomic information that included their
employment, average weekly earnings and average
weekly health expenditure. Paired t-tests were performed
to compare earnings and health expenditure between
the two groups. As questionnaire responses were subject
to recall bias, all 10 cases and controls participating in
the GPS data logger exercise were also asked to record
their daily earnings and health expenditure over the
3 week period. Due to the small sample size, the
Wilcoxon signed-rank test was again used to compare
the two groups.
Results
Of the 31 cases and control pairs participating in the
main study (20 in Nchalo, 11 in Bereu), 8 (26%) pairs
were male and 23 (74%) pairs were female with cases
and controls having a mean age of 58 and 55 respect-
ively. Of the 31 cases, 22 had lymphoedema in one leg, 4
had lymphoedema in both legs, 3 had lymphoedema in
one arm and 2 had lymphoedema in one arm and one
leg. Employment levels were similar between the two
groups (77.4% [24/31] cases, 74.2% [23/31] control), with
all 47 employed participants reporting to be farmers.
QoL questionnaire
With regards to the self-assessed QoL questionnaire,
cases had a mean QoL score of 32.2 (sd = 14.1) in com-
parison to 6.0 (sd = 10.9) for controls, with the average
difference of 26.2 being statistically significantly different
(P < 0.01, 95% CI = [20.9, 31.4]). Table 1 presents these
results, in addition to the individual category scores for
cases and controls. Significant differences in scores were
seen in all five categories, with the largest difference
occurring in mobility (43.1 in cases, 7.4 in controls,
P < 0.01) and psychological health (40.8 in cases, 9.8
in controls, P < 0.01), followed closely by usual activities
(35.9 in cases, 5.8 in controls, P < 0.01). There was gener-
ally more variability in the responses of cases in compari-
son to controls, particularly with regards to the average
mobility score (sd = 25.3 for case, 2.7 for controls). In
comparing the scores of the severe cases (6/31) to that of
the less severe cases (25/31), only a small difference
was observed between the two groups (severe: mean
mobility score = 48.3, sd = 23.4; less severe: mean mo-
bility score = 41.8, sd = 26.1) which may explain some
of this variability, however the difference in within-
group variability was still considered to be large. With
regards to the additional questions directed to cases
only, all but two (94% of 31 responses) had experienced at
least one acute attack in the past 6 months, with the num-
ber of attacks ranging from one to ‘uncountable’. Of the
26 that reported an exact number, the median value was
2. When asked whether they felt that their lymphoedema
affected the number of hours they were able to work, 92%
of respondents (24/26) believed that it did. Of the
remaining two, one had a moderate lymphoedema (both
legs affected) and one had a severe lymphoedema (one leg
affected).
Timed mobility tests
The results of the 10MWT and the TUG tests (Table 2)
showed on average, cases are slower than controls in
both of these tests (10WT: cases = 0.828 m/s (sd = 0.216),
controls = 1.104 m/s (sd = 0.303), P < 0.01; TUG: cases =
14.7 s (sd = 5.500), controls = 11.2 s (sd = 3.622), P < 0.01).
It was also noted that males were marginally quicker than
females (see Additional file +2). In comparing the cases,
more severe cases were on average slower than less severe
cases in both the 10MWT (severe: mean = 0.734 m/s,
sd = 0.258; less severe: mean = 0.850 m/s, sd = 0.204)
and the TUG tests (severe: mean = 16.1, sd = 7.189;
less severe: mean = 14.3 s, sd = 5.141), although neither of
the differences were significant, possibly due to the small
sample size.
Table 3 presents the correlation between perceived
QoL (both overall score, and mobility score) and the re-
sults of the 10MWT and the TUG tests. The relationship
between the mobility tests and the perceived QoL in
controls was consistent for both tests when considering
both the overall QoL score and the mobility score only.
With regards to the cases, there was a very weak,
Table 1 Summary of scores obtained using the self-assessed QoL questionnaire for cases and control
Category Cases Control 95% CI of difference P-value
Mean SD Mean SD
Overall 32.2 14.1 6.0 10.9 20.9–31.4 <0.01
Mobility 43.1 25.3 7.4 2.7 26.1–45.2 <0.01
Self-care 16.3 15.0 1.0 9.8 9.7–20.9 <0.01
Usual activities 35.9 19.8 5.8 6.6 22.9–37.4 <0.01
Psychological health 40.8 17.2 9.8 5.6 24.3–37.7 <0.01
Social participation 25.0 12.1 6.3 5.9 13.8–23.6 <0.01
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non-significant negative relationship observed between
the 10MWT and the overall scores (correlation =
−0.12, 95% CI = (−0.45, 0.25)) and mobility scores
(correlation = −0.06, 95% CI = (−0.41, 0.30)), whereas a
slightly stronger, yet still non-significant negative correl-
ation was observed between the TUG test and the overall
QoL scores (correlation = 0.30, 95% CI = (−0.06, 0.59)) and
mobility scores (correlation = 0.18, 95% CI = (−0.19, 0.50))
(Fig. 1). This indicates that self-assessed physical disability
differed from objectively measured physical disability in
the cases, whereas the two measures were consistent for
the controls.
Natural mobility measures
Summaries of the GPS data, recorded for 10 cases and
10 controls over approximately a 3 week period (20 days
on average for cases, 21 days for controls), are presented
in Table 4. The minimum convex polygon activity area
was calculated using all GPS coordinates collected over
this time period. The kernel density activity area was cal-
culated using a 10 m resolution grid, and the value of
the smoothing parameter h was obtained using the me-
dian “reference” bandwidth calculated using the cases
data only i.e. h = 30. Figure 2 presents a visualisation of
these results for one participant. In this example 28.279
points were collected over a 24 day period, and the
resulting minimum convex polygon activity area was
1.85 km2, whereas the 99% kernel density activity area
was 1.05 km2. No significant differences between cases
and controls were observed between any of the summary
measures under consideration, however the median
value for the cases was consistently lower than that of
the controls i.e. cases moved shorter distances (median
= 16.28 km/day for cases vs 19.23 km/day for controls)
and moved at a slower speed (median = 0.186 m/s for
cases vs 0.209 m/s for controls). The activity area for
cases was generally smaller than that of controls using
both measurement methods i.e. the median for cases
was 4.30 km2 in comparison to 7.14 km2 for controls
using the minimum convex polygon method, and
1.25 km2 for cases in comparison to 2.10 km2 for con-
trols using the kernel smoothing method.
Table 5 presents the value of Kendall’s tau between
the two activity area measures and the self-assessed
QoL scores and timed mobility tests. No significant
associations were observed between the self-assessed
overall QoL and mobility scores and the home range
measures, although may be as a consequence of the
small sample size. With regards to the timed mobility
tests, (borderline) significant correlation was observed
between both activity area measures for the 10MWT
(MCP: tau = 0.45, 95% CI = (0.030, 0.869); KS: tau = 0.58,
95% CI = (0.193, 0.976)) and the TUG test (MCP:
tau = −0.42, 95% CI = (−0.792, −0.048); KS: tau = −0.47,
95% CI = (−0.933, −0.001)), whereas there were no sig-
nificant relationships observed for the controls. This is in
contrast to the relationships observed between the self-
assessed QoL scores and the timed mobility tests, in
which the results for the controls were significant, but
with the cases they were not.
Income and health expenditure
In comparing the questionnaire responses of the 31
cases and control, overall the two groups were similar in
employment (77% [24/31] of cases, 74% [23/31] of
controls), however, on average, cases were unable to
work for 17 days over the previous 3 months on average
(min = 0, max = 60), whereas no controls reported being
unable to work (P < 0.01). The average self-reported
weekly earnings were lower in cases (708MK vs 1 259MK,
Table 2 Summaries of the timed mobility tests (10 m walking test speed, and time to complete the timed up and go test)
Timed tests Mean SD 95% CI of difference P-value
10 m walking test (m/s) Cases 0.828 0.216 0.165–0.387 <0.01
Controls 1.104 0.303
Timed up and go (secs) Cases 14.7 5.500 −5.354, −1.731 <0.01
Controls 11.2 3.622
Table 3 Correlation between the self-assessed disability and mobility scores and the timed mobility tests
Test Overall disability score Mobility score
Correlation 95% CI Correlation 95% CI
10 m walking test (m/s) Cases −0.12 −0.45, 0.25 −0.06 −0.41, 0.30
Controls −0.63 −0.80, −0.36 −0.61 −0.79, −0.34
Timed up and go (secs) Cases 0.30 −0.06, 0.59 0.18 −0.19, 0.50
Controls 0.75 0.52, 0.87 0.77 0.57, 0.88
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P = 0.364), although this difference was not statistically
significant. Further, there was a non-significant difference
in the average amount spent on health in the previ-
ous 3 months (cases = 3 383MK, controls = 2 258MK,
P = 0.363), with 6 cases (20%, 30 responses) and 8
control (26%, 31 responses) reporting that they accessed
free government healthcare only.
With regards to the daily income and expenditure data
collected during the GPS data logger exercise (Table 6), me-
dian weekly earnings for cases was close to three times
greater than that of controls (cases = 527MK, controls = 1
393MK, P = 0.064), with this difference being borderline
significant. This differed from the self-reported weekly
earnings provided by this subset of participants (cases =
500MK, controls = 800MK) during the questionnaire. In
comparing median weekly health expenditure, cases spent
less than controls in both absolute (cases = 147MK, con-
trols = 278MK, P = 0.359) and relative terms (cases % of
earnings = 16%, controls % of earnings = 22%, P = 0.461) al-
though neither of these differences were significant.
Discussion
This study contributes to the growing body of evidence
on the physical, social and economic impact of lym-
phoedema [2, 15], and in particular is one of the few
studies that objectively quantifies the relative impact
of lymphoedema on mobility, in comparison to an
unaffected cohort of controls with a similar age distri-
bution and occupational status. It is clear from this
study that those affected by lymphoedema are at a
Fig. 1 Scatterplots of the results of the mobility score against the 10MWT speeds a and TUG test times b. Cases and controls are represented by
red and black dots respectively
Table 4 Summaries of the GPS data logger measurements for cases and controls
Timed tests Median Q1 Q3 P-value
Average distance (km/day) Cases 16.28 14.97 19.41 0.375
Controls 19.23 16.38 20.16
Average speed (m/s) Cases 0.186 0.172 0.237 0.625
Controls 0.209 0.183 0.244
Home range (minimum convex polygon) km2 Cases 4.30 0.84 23.16 0.375
Controls 7.14 4.60 19.92
99% Home range (kernel smoothing) km2 Cases 1.25 0.51 2.75 0.160
Controls 2.10 1.11 3.09
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disadvantage to their unaffected peers, experiencing a
lower quality of life, particularly with regards to their
level of mobility, as confirmed by both the subjective
QoL survey responses and objective timed test results
and GPS data collected during this study. To the au-
thors’ knowledge, this is the first time that the latter
two approaches have been used to measure mobility
in lymphoedema cases in LF-endemic areas. This
study further supports previous work of the economic
consequences of lymphoedema, or neglected tropical
diseases (NTDs) in general [6, 7, 28], with controls’
median weekly earnings over the 3 week study period
(1 393MK, ~$1.86) being three times greater than
that of cases (527MK, ~$0.70).
Fig. 2 Example GPS points for one participant: a activity area for the participant as a minimum convex polygon, b activity area obtained using
99% kernel density smoothing of the GPS points
Table 5 Kendall’s rank correlation (Kendall’s tau) between activity area measures and self-assessed score and timed mobility test results
Minimum convex polygon activity area Kernel smoothing activity area
Correlation (tau) 95% CI Correlation (tau) 95% CI
Disability score Cases −0.02 −0.592, 0.547 −0.15 −0.678, 0.360
Controls −0.05 −0.686, 0.594 −0.05 −0.530, 0.438
Mobility score Cases −0.04 −0.481, 0.391 −0.13 −0.666, 0.396
Controls 0.11 −0.355, 0.566 −0.11 −0.566, 0.355
10 m walking test (m/s) Cases 0.45 0.030, 0.869 0.58 0.193, 0.976
Controls 0.31 −0.163, 0.792 0.31 −0.235, 0.864
Timed up and go (m/s) Cases −0.42 −0.797, −0.048 −0.47 −0.933, −0.001
Controls −0.38 −0.767, 0.011 −0.38 −0.900, 0.145
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With regards to the measures used, this study indi-
cates that objective measures of physical disability such
as the 10 m walking test and the timed up and go test
are a useful supplement to QoL questionnaires when
assessing the impact of LF morbidity management inter-
ventions. These two measures were uncorrelated in
cases, indicating that self-assessed disability and mea-
sured disability differed in this cohort. It may there-
fore be the case that another aspect of the
lymphoedema is having a greater impact on the case’s
perceived disability, for example the frequency or dur-
ation of acute attacks. This lack of a relationship be-
tween the QoL score (both overall and mobility) for
the cases therefore indicates that when assessing the
physical impact of lymphoedema, multiple measure-
ments should be considered to obtain an accurate
picture of the impact in terms of both perceived and
measurable disability. Further, detailed longitudinal
mobility data such as that obtained by the GPS data
logger may allow assessments of physical ability to be
made in a more natural setting. This study indicates
that the activity area measure is most closely associ-
ated with mobility under test conditions for cases
only, whereas no association was observed for con-
trols; thus further work is needed to determine how
GPS data can best be used to assess mobility im-
provements. Whilst the use of the GPS data loggers
was labour intensive due to the need to frequently
charge the devices, advances in GPS-enabled wearable
technologies will likely make this level of assessment
more accessible in the future [29].
Conclusions
This study highlights the importance of ensuring that
continued efforts be made to address the negative
health, social and economic impacts of filarial lymphoe-
dema and their associated acute attacks. Appropriate
quality of life and mobility measures such as those de-
scribed in this study will enable the effectiveness of fu-
ture clinical and other therapeutic interventions to be
evaluated, and the full benefit of morbidity management
activities to be realised.
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